(1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:

(a) 9 mg of budesonide;

(b) hydroxypropyl cellulose; and

(c) magnesium stearate, stearic acid, or a mixture thereof;

and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides an $AUC_{0\text{-}infinity}$, of said budesonide in said human of about 16431.2±10519.8 (pg)×(h)/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.

22. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:

(a) 9 mg of budesonide;

(b) hydroxypropyl cellulose; and

(c) magnesium stearate, stearic acid, or a mixture thereof;

and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides a C_{max} of said budesonide in said human of about 1348.8±958.8 pg/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.

* * * * *